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Evaluation of a new rapid test for the detection of influenza A and B viruses and pandemic (H1N1) 2009 virus subtyping in respiratory samples
The emergence in 2009 of a novel influenza A (H1N1) virus was responsible for a pandemic outbreak of febrile respiratory infections worldwide (NSOIAVIT, 2009) . During the first pandemic wave, specific real-time RT-PCR (rRT-PCR) assays were the reference methods for the detection of the pandemic (H1N1) 2009 influenza virus, leading to the overload of laboratory facilities due to the large number of clinical samples analysed (Duchamp et al., 2010) . The re-emergence during winter 2011 of the pandemic (H1N1) 2009 virus highlighted the need for commercially available and readily performed influenza diagnostic tests capable of detecting and subtyping influenza A viral strains in respiratory samples. The previously reported sensitivity of commercially available rapid influenza antigen tests (RIATs) for pandemic (H1N1) 2009 virus was 11 to 80 %, and generally evaluated at around 60 % for clinical specimens (Drexler et al., 2009; Lee et al., 2010; Lévêque et al., 2010; Louie et al., 2010) . Moreover, currently available RIATs are only able to type influenza A and B viruses, and do not specifically subtype the pandemic (H1N1) 2009 virus. The aim of this study was thus to assess the diagnostic performances, comparatively to the rRT-PCR assay, of a new RIAT, the ONE STEP influenza virus A/B/A(H1N1) pandemic rapid test (Standard Diagnostics; Bioline), which can detect the influenza viruses A and B, and subtype the pandemic (H1N1) 2009 in respiratory samples.
One hundred and six nasal swab specimens collected in SeptemberDecember 2009 from patients of all age groups with influenza-like illness were retrospectively tested by RIAT. The Virocult system (Lakewood Biochemical), consisting of a rayon-budded swab and a transport tube of liquid virus transport medium, was used. Among the 106 clinical samples investigated, 56 had previously tested positive for pandemic (H1N1) 2009 influenza virus by H1 specific rRT-PCR assay (Duchamp et al., 2010) . A total of 40 samples had previously tested positive for seasonal influenza A virus [10 (H1N1) and 20 (H3N2) influenza A virus specimens] or influenza B virus (10 specimens) by influenza A and B specific rRT-PCR assays developed by the French National Reference Centres for influenza viruses. Ten samples negative by rRT-PCR assays for influenza A and B viruses were also randomly selected. Nasal swab samples were rapidly transported to the virology laboratory (Reims University Medical Centre, Reims, France) where 500 ml virus transport medium was added to the Virocult system, then each sample was divided between two sterile tubes. The first aliquot was prospectively tested for pandemic and seasonal influenza A and B viruses, while the second aliquot was used for the retrospective RIAT analysis. The ONE STEP influenza virus A/B/A(H1N1) pandemic rapid test is a chromatographic immunoassay with strips with immobilized mouse monoclonal anti-A(H1N1) pandemic haemagglutinin, anti-influenza A and anti-influenza B nucleoprotein antibodies. The RIAT was carried out according to the manufacturer's instructions using 100 ml of the second aliquot stored at 280 u C.
Overall, from the 56 specimens positive for the pandemic (H1N1) 2009 influenza virus, the new rapid antigen test detected 22 positive samples, demonstrating a sensitivity of 39.3 % (range 26.5-52.1 %). This appeared to be lower than the sensitivity range 68.5-77 % recently reported in similar studies testing the same RIAT with the same sampling technique in comparison with a rRT-PCR assay (Choi et al., 2010; Kwon et al., 2011) . A potential effect of the storage at 280 u C on the target antigens detected by the RIAT could not be ruled out, in particular in cases of low viral (Fig. 1) . A receiver operating characteristics (ROC) analysis was also performed, showing an area under the curve of 0.804 (ROC value range 0.689-0.918) and confirming that the RIAT results were well correlated with the viral load quantified by the M rRT-PCR specific assay in the clinical samples. In this study, the smallest viral load detected in a clinical sample by the RIAT was 3.5610 3 M gene copies ml Correspondence
